DOCSLIB.ORG

Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2015/11/18/jpet.115.226910.DC1 1521-0103/356/2/293–304$25.00 http://dx.doi.org/10.1124/jpet.115.226910 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 356:293–304, February 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Evidence for Classical Cholinergic Toxicity Associated with s Selective Activation of M1 Muscarinic Receptors Andrew Alt, Annapurna Pendri, Robert L. Bertekap, Jr., Guo Li, Yulia Benitex, Michelle Nophsker, Kristin L. Rockwell, Neil T. Burford, Chi Shing Sum, Jing Chen, John J. Herbst, Meredith Ferrante, Adam Hendricson, Mary Ellen Cvijic, Ryan S. Westphal, Jonathan O’Connell, Martyn Banks, Litao Zhang, Robert G. Gentles, Susan Jenkins, James Loy, and John E. Macor Research and Development/Discovery, Bristol-Myers Squibb Company, Wallingford, Connecticut (A.A., A.P., R.L.B., G.L., Y.B., M.N., K.L.R, N.T.B., J.J.H., M.F., A.H., R.S.W., J.O., M.B., R.G., S.J., J.L.); Research and Development/Discovery, Bristol-Myers Downloaded from Squibb Company, Hopewell, New Jersey (C.S.S., M.E.C.); and Research and Development/Discovery, Bristol-Myers Squibb Company, Lawrence Township, New Jersey (J.C., L.Z., J.E.M.) Received June 19, 2015; accepted November 17, 2015 ABSTRACT jpet.aspetjournals.org The muscarinic acetylcholine receptor subtype 1 (M1) receptors activities that are highly functionally selective for the M1 receptor play an important role in cognition and memory, and are were tested in rats, dogs, and cynomologous monkeys: considered to be attractive targets for the development of novel (3-((1S,2S)-2-hydrocyclohexyl)-6-((6-(1-methyl-1H-pyrazol-4-yl) medications to treat cognitive impairments seen in schizophre- pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one; 1-((4-cyano- nia and Alzheimer’s disease. Indeed, the M1 agonist xanomeline 4-(pyridin-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine- has been shown to produce beneficial cognitive effects in both 3-carboxylic acid; and (R)-ethyl 3-(2-methylbenzamido)-[1, ’ 9 9 Alzheimer s disease and schizophrenia patients. Unfortunately, 4 -bipiperidine]-1 -carboxylate). Despite their selectivity for the at ASPET Journals on September 28, 2021 the therapeutic utility of xanomeline was limited by cholinergic M1 receptor, all three compounds elicited cholinergic side effects side effects (sweating, salivation, gastrointestinal distress), such as salivation, diarrhea, and emesis. These effects could not which are believed to result from nonselective activation of other be explained by activity at other muscarinic receptor subtypes, muscarinic receptor subtypes such as M2 and M3. Therefore, or by activity at other receptors tested. Together, these results drug discovery efforts targeting the M1 receptor have focused on suggest that activation of M1 receptors alone is sufficient to the discovery of compounds with improved selectivity profiles. produce unwanted cholinergic side effects such as those seen Recently, allosteric M1 receptor ligands have been described, with xanomeline. This has important implications for the devel- which exhibit excellent selectivity for M1 over other muscarinic opment of M1 receptor–targeted therapeutics since it suggests receptor subtypes. In the current study, the following three that dose-limiting cholinergic side effects still reside in M1 compounds with mixed agonist/positive allosteric modulator receptor selective activators. Introduction subtypes each represent separate gene products and exhibit distinct signaling pathways and tissue distribution, although The neurotransmitter acetylcholine activates two distinct all are expressed within the central nervous system (Ishii and families of receptors: nicotinic and muscarinic acetylcholine Kurachi 2006). receptors, which were initially classified based upon their The M1 muscarinic receptors play an important role in differential activation by the toxins nicotine (Lindstrom 1997) multiple domains of cognitive function (Felder et al., 2000; and muscarine (Wess et al., 1996). Nicotinic acetylcholine Auld et al., 2002), and a significant body of evidence suggests receptors are ligand-gated ion channels; muscarinic acetylcho- that activation of M1 receptors can produce therapeutically line receptors are seven transmembrane guanine nucleotide beneficial effects for the treatment of schizophrenia and binding protein (G protein) coupled receptors. Five subtypes of Alzheimer’s disease (Langmead et al., 2008). Muscarinic – muscarinic acetylcholine receptors exist (M1 M5). These five receptor activation has been shown to reverse cognitive and behavioral deficits in animal models of schizophrenia and ’ dx.doi.org/10.1124/jpet.115.226910. Alzheimer s disease, and the M1 receptor specifically has been s This article has supplemental material available at jpet.aspetjournals.org. implicated in mediating these effects (Jones et al., 2005; ABBREVIATIONS: ago, agonist; AUC, area under the curve; compound A, 3-((1S,2S)-2-hydrocyclohexyl)-6-((6-(1-methyl-1H-pyrazol-4-yl)pyridin- 3-yl)methyl)benzo[h]quinazolin-4(3H)-one; compound B, 1-((4-cyano-4-(pyridin-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid; compound C, (R)-ethyl 3-(2-methylbenzamido)-[1,49-bipiperidine]-19-carboxylate; DMSO, dimethylsulfoxide; G protein, guanine nucleotide binding protein; M1–M5, muscarinic acetylcholine receptor subtypes 1–5; PAM, positive allosteric modulator; PEG, polyethylene glycol; t1/2, half-life; Vss, steady-state volume of distribution. 293 294 Alt et al. Langmead et al., 2008; Barak and Weiner 2011; Fisher 2008). following three structurally distinct M1 PAMs were chosen The most direct evidence for the utility of M1 activators in from the scientific literature (Kuduk et al., 2011; Lebois treating schizophrenia and Alzheimer’s disease comes from et al., 2011): compound A, (3-((1S,2S)-2-hydrocyclohexyl)-6- clinical trials using xanomeline, a muscarinic partial agonist ((6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)methyl)benzo[h] with modest selectivity for M1 and M4 receptors. Xanomeline quinazolin-4(3H)-one; compound B, 1-((4-cyano-4-(pyridin- was shown to improve psychosis and behavioral disturbances 2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic in Alzheimer’s disease patients (Bodick et al., 1997). Xanomeline acid; and compound C, (R)-ethyl 3-(2-methylbenzamido)-[1,49- was also found to produce both significant psychiatric im- bipiperidine]-19-carboxylate (Fig. 1). These compounds display provements, and improvements in learning and memory in potency and pharmacokinetic profiles that make them appro- schizophrenia patients (Shekhar et al., 2008). Unfortunately, priate for in vivo testing; and, importantly, they show excellent the clinical utility of xanomeline is limited by its side-effect selectivity for M1 over other muscarinic receptor subtypes in profile, which includes salivation, sweating, and gastrointes- vitro. In this study, the safety profile of these selective M1 tinal distress—all of which are classic cholinergic side effects. ligands was investigated in rats, dogs, and cynomologous Thesesideeffectsarebelievedtobeduetoactivityof monkeys. Despite their selectivity for M1, all three compounds were found to produce effects associated with classic cholinergic xanomeline at M2 and M3 muscarinic receptors (Melancon et al., 2013). Therefore, selectivity has remained the major toxicity such as salivation and diarrhea. Accordingly, these focus for drug discovery efforts targeting the M receptor. results refute the original hypothesis and instead provide 1 Downloaded from evidence to suggest that activation of the M receptor alone is However, attaining sufficient selectivity for M1 versus other 1 muscarinic receptors to avoid cholinergic side effects has sufficient to produce cholinergic toxicity in animals. proven to be very challenging because the acetylcholine binding site is highly conserved within all five muscarinic Materials and Methods receptor subtypes (Heinrich et al., 2009), and despite years of medicinal chemistry efforts acetylcholine site activators with Cells jpet.aspetjournals.org sufficient M1 selectivity have not been identified. M2,M3, and M4 were recombinantly expressed in a Chinese An alternative pharmacological strategy is to modulate the hamster ovary cell background, with M2 and M4 lines also containing activity of M1 receptors using molecules that bind to allosteric a construct expressing Gqi5 and aequorin. The M1- and M5-expressing sites that are distinct from the acetylcholine (orthosteric) cell lines were generated by recombinant expression of M1 or M5 in binding site. Small-molecule positive allosteric modulators Chinese hamster ovary A12 cells (Perkin-Elmer, Akron, OH). – (PAMs) have been identified for many G protein coupled Cells were cultured in tissue culture treated T-175 flasks (Corning, Corning, NY) in medium [Dulbecco’s modified Eagle’s medium/F12 receptors (Wootten et al., 2013), including the M1 receptor (Gibco, Waltham, MA), 10% fetal bovine serum (Hyclone, Logan, at ASPET Journals on September 28, 2021 (Melancon et al., 2013). Allosteric binding sites do not face the Utah), and appropriate selection antibiotics] at 37°C, 5% CO2. Cells same evolutionary pressure as the orthosteric binding site, were harvested and plated onto 384-well (Corning) tissue which must bind the endogenous agonist to maintain receptor culture–treated black/clear plates 16–20 hours prior to the
Load more

Recommended publications
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • G Protein-Coupled Receptors As Therapeutic Targets for Multiple Sclerosis
    npg GPCRs as therapeutic targets for MS Cell Research (2012) 22:1108-1128. 1108 © 2012 IBCB, SIBS, CAS All rights reserved 1001-0602/12 $ 32.00 npg REVIEW www.nature.com/cr G protein-coupled receptors as therapeutic targets for multiple sclerosis Changsheng Du1, Xin Xie1, 2 1Laboratory of Receptor-Based BioMedicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sci- ences and Technology, Tongji University, Shanghai 200092, China; 2State Key Laboratory of Drug Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shou Jing Road, Pudong New District, Shanghai 201203, China G protein-coupled receptors (GPCRs) mediate most of our physiological responses to hormones, neurotransmit- ters and environmental stimulants. They are considered as the most successful therapeutic targets for a broad spec- trum of diseases. Multiple sclerosis (MS) is an inflammatory disease that is characterized by immune-mediated de- myelination and degeneration of the central nervous system (CNS). It is the leading cause of non-traumatic disability in young adults. Great progress has been made over the past few decades in understanding the pathogenesis of MS. Numerous data from animal and clinical studies indicate that many GPCRs are critically involved in various aspects of MS pathogenesis, including antigen presentation, cytokine production, T-cell differentiation, T-cell proliferation, T-cell invasion, etc. In this review, we summarize the recent findings regarding the expression or functional changes of GPCRs in MS patients or animal models, and the influences of GPCRs on disease severity upon genetic or phar- macological manipulations.
    [Show full text]
  • Two Types of Muscarinic Response to Acetylcholine in Mammalian Cortical Neurons (Clngulate/M Current/Cholinergic/Pirenzepine) DAVID A
    Proc. Nail. Acad. Sci. USA Vol. 82, pp. 6344-6348, September 1985 Neurobiology Two types of muscarinic response to acetylcholine in mammalian cortical neurons (clngulate/M current/cholinergic/pirenzepine) DAVID A. MCCORMICK AND DAVID A. PRINCE Department of Neurology, Room C338, Stanford University School of Medicine, Stanford, CA 94305 Communicated by Richard F. Thompson, May 22, 1985 ABSTRACT Applications of acetylcholine (AcCho) to py- The cerebral cortex contains nicotinic as well as several ramidal cells of guinea pig cingulate cortical slices maintained subtypes of muscarinic AcCho receptors (20-23). Previous in vitro result in a short latency inhibition, followed by a reports suggest that cholinergic slow excitation is mediated prolonged increase in excitability. Cholinergic inhibition is by receptors possessing muscarinic characteristics, while mediated through the rapid excitation of interneurons that cholinergic inhibition may be due to activation of receptors utilize the inhibitory neurotransmitter y-aminobutyric acid that have both nicotinic and muscarinic properties (5, 24). (GABA). This rapid excitation of interneurons is. associated The recent characterization of receptor antagonists (e.g., with a membrane depolarization and a decrease in neuronal pirenzepine) and agonists (e.g., pilocarpine) that are relative- input resistance. In contrast, AcCho-induced excitation of ly specific for subtypes ofmuscarinic receptors (21, 22) raises pyramidal cells is due to a direct action that produces a the question of whether different types of cholinergic re- voltage-dependent increase in input resistance. In the experi- sponses demonstrated physiologically within the central ments reported here, we investigated the possibility that these nervous system might be due to activation of different two responses are mediated by different subclasses of cholin- subclasses of muscarinic receptors, as appears to be the case ergic receptors.
    [Show full text]
  • Role of Muscarinic Acetylcholine Receptors in Adult Neurogenesis and Cholinergic Seizures
    Role of Muscarinic Acetylcholine Receptors in Adult Neurogenesis and Cholinergic Seizures Rebecca L. Kow A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2014 Reding Committee: Neil Nathanson, Chair Sandra Bajjalieh Joseph Beavo Program Authorized to Offer Degree: Pharmacology ©Copyright 2014 Rebecca L. Kow University of Washington Abstract Role of Muscarinic Acetylcholine Receptors in Adult Neurogenesis and Cholinergic Seizures Rebecca L. Kow Chair of the Supervisory Committee: Professor Neil M. Nathanson Department of Pharmacology Muscarinic acetylcholine receptors (mAChRs) are G protein-coupled receptors (GPCRs) that mediate important functions in the periphery and in the central nervous systems. In the brain these receptors modulate many processes including learning, locomotion, pain, and reward behaviors. In this work we investigated the role of mAChRs in adult neurogenesis and further clarified the regulation of muscarinic agonist-induced seizures. We first investigated the role of mAChRs in adult neurogenesis in the subventricular zone (SVZ) and the subgranular zone (SGZ). We were unable to detect any modulation of adult neurogenesis by mAChRs. Administration of muscarinic agonists or antagonists did not alter proliferation or viability of adult neural progenitor cells (aNPCs) in vitro. Similarly, muscarinic agonists did not alter proliferation or survival of new adult cells in vivo. Loss of the predominant mAChR subtype in the forebrain, the M1 receptor, also caused no alterations in adult neurogenesis in vitro or in vivo, indicating that the M1 receptor does not mediate the actions of endogenous acetylcholine on adult neurogenesis. We also investigated the interaction between mAChRs and cannabinoid receptor 1 (CB1) in muscarinic agonist pilocarpine-induced seizures.
    [Show full text]
  • Current Advances in Allosteric Modulation of Muscarinic Receptors
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 18 January 2020 Peer-reviewed version available at Biomolecules 2020, 10, 325; doi:10.3390/biom10020325 Review Current Advances in Allosteric Modulation of Muscarinic Receptors Jan Jakubik 1* and Esam E. El-Fakahany 2* 1 Department of Neurochemistry, Institute of Physiology CAS, Prague, Czech Republic; [email protected] 2 Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN, USA; [email protected] * Correspondence: [email protected]; [email protected] Abstract: Allosteric modulators are ligands that bind to a site on the receptor that is spatially separated from the orthosteric binding site for the endogenous neurotransmitter. Allosteric modulators modulate the binding affinity, potency and efficacy of orthosteric ligands. Muscarinic acetylcholine receptors are prototypical allosterically-modulated G-protein-coupled receptors. They are a potential therapeutic target for the treatment of psychiatric, neurologic and internal diseases like schizophrenia, Alzheimer’s disease, Huntington disease, type 2 diabetes or chronic pulmonary obstruction. Here we review progress made during the last decade in our understanding of their mechanisms of binding, allosteric modulation and in vivo actions of in order to understand the translational impact of studying this important class of pharmacological agents. We overview newly developed allosteric modulators of muscarinic receptors as well as new spin-off ideas like bitopic ligands combining allosteric and orthosteric moieties and photo-switchable ligands based on bitopic agents. Keywords: acetylcholine; muscarinic receptors; allosteric modulation 1. Introduction Slow metabotropic responses to acetylcholine are mediated by muscarinic receptors. Five distinct subtypes of muscarinic acetylcholine receptors (M1-M5) have been identified in the human genome[1].
    [Show full text]
  • Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’
    0270.6474/85/0505-1202$02.00/O The Journal of Neuroscience CopyrIght 0 Society for Neuroscrence Vol. 5, No. 5, pp. 1202-1207 Printed in U.S.A. May 1985 Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’ EDWIN M. MEYER* AND DEBORAH H. OTERO Department of Pharmacology and Therapeutics, University of Florida School of Medicine, Gainesville, Florida 32610 Abstract brain (Gonzales and Crews, 1984). M,-receptors, however, appear pre- and postsynaptically in brain, are regulated by an intrinsic The muscarinic receptors that modulate acetylcholine membrane protein that binds to GTP (g-protein), and may not be release from rat cortical synaptosomes were characterized coupled to changes in phosphatidylinositol turnover. with respect to sensitivity to drugs that act selectively at M, The present studies were designed to determine whether M,- or or Ma receptor subtypes, as well as to changes in ionic Mp-receptors mediate the presynaptic modulation of ACh release. strength and membrane potential. The modulatory receptors These studies involve dose-response curves for the release of appear to be of the M2 type, since they are activated by synaptosomal [3H]ACh in the presence of selected muscarinic ago- carbachol, acetylcholine, methacholine, oxotremorine, and nists and antagonists, as well as treatments that selectively alter MI- bethanechol, but not by pilocarpine, and are blocked by or M,-receptor activity. Our results indicate that the presynaptic atropine, scopolamine, and gallamine (at high concentra- modulation of [3H]ACh release is mediated by MP- but not MI- tions), but not by pirenzepine or dicyclomine.
    [Show full text]
  • Defects of the Glycinergic Synapse in Zebrafish
    fnmol-09-00050 June 28, 2016 Time: 16:28 # 1 View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Frontiers - Publisher Connector REVIEW published: 29 June 2016 doi: 10.3389/fnmol.2016.00050 Defects of the Glycinergic Synapse in Zebrafish Kazutoyo Ogino* and Hiromi Hirata* Department of Chemistry and Biological Science, College of Science and Engineering, Aoyama Gakuin University, Sagamihara, Japan Glycine mediates fast inhibitory synaptic transmission. Physiological importance of the glycinergic synapse is well established in the brainstem and the spinal cord. In humans, the loss of glycinergic function in the spinal cord and brainstem leads to hyperekplexia, which is characterized by an excess startle reflex to sudden acoustic or tactile stimulation. In addition, glycinergic synapses in this region are also involved in the regulation of respiration and locomotion, and in the nociceptive processing. The importance of the glycinergic synapse is conserved across vertebrate species. A teleost fish, the zebrafish, offers several advantages as a vertebrate model for research of glycinergic synapse. Mutagenesis screens in zebrafish have isolated two motor defective mutants that have pathogenic mutations in glycinergic synaptic transmission: bandoneon (beo) and shocked (sho). Beo mutants have a loss-of-function mutation of glycine receptor (GlyR) b-subunit b, alternatively, sho mutant is a glycinergic transporter 1 (GlyT1) defective mutant. These mutants are useful animal models for understanding of glycinergic synaptic transmission and for identification of novel therapeutic agents for human diseases arising from defect in glycinergic transmission, such as hyperekplexia or glycine encephalopathy. Recent advances in techniques for genome editing and for Edited by: Robert J.
    [Show full text]
  • Neuronal Nicotinic Receptors
    NEURONAL NICOTINIC RECEPTORS Dr Christopher G V Sharples and preparations lend themselves to physiological and pharmacological investigations, and there followed a Professor Susan Wonnacott period of intense study of the properties of nAChR- mediating transmission at these sites. nAChRs at the Department of Biology and Biochemistry, muscle endplate and in sympathetic ganglia could be University of Bath, Bath BA2 7AY, UK distinguished by their respective preferences for C10 and C6 polymethylene bistrimethylammonium Susan Wonnacott is Professor of compounds, notably decamethonium and Neuroscience and Christopher Sharples is a hexamethonium,5 providing the first hint of diversity post-doctoral research officer within the among nAChRs. Department of Biology and Biochemistry at Biochemical approaches to elucidate the structure the University of Bath. Their research and function of the nAChR protein in the 1970’s were focuses on understanding the molecular and facilitated by the abundance of nicotinic synapses cellular events underlying the effects of akin to the muscle endplate, in electric organs of the acute and chronic nicotinic receptor electric ray,Torpedo , and eel, Electrophorus . High stimulation. This is with the goal of affinity snakea -toxins, principallyaa -bungarotoxin ( - Bgt), enabled the nAChR protein to be purified, and elucidating the structure, function and subsequently resolved into 4 different subunits regulation of neuronal nicotinic receptors. designateda ,bg , and d .6 An additional subunit, e , was subsequently identified in adult muscle. In the early 1980’s, these subunits were cloned and sequenced, The nicotinic acetylcholine receptor (nAChR) arguably and the era of the molecular analysis of the nAChR has the longest history of experimental study of any commenced.
    [Show full text]
  • [3H]Acetylcholine to Muscarinic Cholinergic Receptors’
    0270.6474/85/0506-1577$02.00/O The Journal of Neuroscience CopyrIght 0 Smety for Neurosmnce Vol. 5, No. 6, pp. 1577-1582 Prrnted rn U S.A. June 1985 High-affinity Binding of [3H]Acetylcholine to Muscarinic Cholinergic Receptors’ KENNETH J. KELLAR,2 ANDREA M. MARTINO, DONALD P. HALL, Jr., ROCHELLE D. SCHWARTZ,3 AND RICHARD L. TAYLOR Department of Pharmacology, Georgetown University, Schools of Medicine and Dentistry, Washington, DC 20007 Abstract affinities (Birdsall et al., 1978). Evidence for this was obtained using the agonist ligand [3H]oxotremorine-M (Birdsall et al., 1978). High-affinity binding of [3H]acetylcholine to muscarinic Studies of the actions of muscarinic agonists and detailed analy- cholinergic sites in rat CNS and peripheral tissues was meas- ses of binding competition curves between muscarinic agonists and ured in the presence of cytisin, which occupies nicotinic [3H]antagonists have led to the concept of muscarinic receptor cholinergic receptors. The muscarinic sites were character- subtypes (Rattan and Goyal, 1974; Goyal and Rattan, 1978; Birdsall ized with regard to binding kinetics, pharmacology, anatom- et al., 1978). This concept was reinforced by the discovery of the ical distribution, and regulation by guanyl nucleotides. These selective actions and binding properties of the antagonist pirenze- binding sites have characteristics of high-affinity muscarinic pine (Hammer et al., 1980; Hammer and Giachetti, 1982; Watson et cholinergic receptors with a Kd of approximately 30 nM. Most al., 1983; Luthin and Wolfe, 1984). An evolving classification scheme of the muscarinic agonist and antagonist drugs tested have for these muscarinic receptors divides them into M-l and M-2 high affinity for the [3H]acetylcholine binding site, but piren- subtypes (Goyal and Rattan, 1978; for reviews, see Hirschowitz et zepine, an antagonist which is selective for M-l receptors, al., 1984).
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • The Pharmacology of the Autonomic Nervous System Oliver Pratt, Carl Gwinnutt* *Correspondence Email: [email protected]
    Update in Anaesthesia Originally published in Anaesthesia Tutorial of the Week (2007) The Pharmacology of the Autonomic Nervous System Oliver Pratt, Carl Gwinnutt* *Correspondence Email: [email protected] INTRODUCTION Summary In our article describing the anatomy and function of A balance exists between the autonomic nervous system (this edition, page 37), sympathetic and parasympathetic outflow. we saw that: Many common pathologies • The autonomic nervous system (ANS) reflexes are and surgical procedures can instrumental in the control of most of the body’s affect this balance, leading organ systems. to disturbances in the function of organ systems. • The afferent limb of these reflexes can be from Drugs can contribute to the ANS or central nervous system (CNS). The autonomic disturbance, Figure 1. The effects of major drug groups on the ‘auto- efferent limb is mediated by the sympathetic but drugs can also be used nomic equilibrium’ to redress the balance. (SNS) or parasympathetic (PNS) divisions, which Those acting on the ANS, are functionally and structurally distinct. The autonomic effects of a drug may be the primary tend to be agonists or intended action – for example the sympathomimetic antagonists at one or more • The observed physiological effect will depend actions of dobutamine, or secondary effects – for of the various receptors, upon which neurotransmitter and types of receptors example the parasympathomimetic action of repeated and this determines their are involved. doses of succinylcholine. clinical effects. Some have slightly different • In the normal, resting situation equilibrium exists In the remainder of this article, we will give an overview modes of action (such as between sympathetic and parasympathetic activity.
    [Show full text]
  • Cholinergic Receptor Subtypes and Their Role in Cognition, Emotion, and Vigilance Control: an Overview of Preclinical and Clinical Findings
    Psychopharmacology (2011) 215:205–229 DOI 10.1007/s00213-010-2153-8 REVIEW Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: An overview of preclinical and clinical findings Susanne Graef & Peter Schönknecht & Osama Sabri & Ulrich Hegerl Received: 15 June 2010 /Accepted: 15 December 2010 /Published online: 8 January 2011 # Springer-Verlag 2011 Abstract memory, whereas the α4β2* subtype has been linked to Rationale The cholinergic system has long been linked to tests of attention. Both muscarinic and nicotinic cholinergic cognitive processes. Two main classes of acetylcholine mechanisms play a role in modulating brain electrical (ACh) receptors exist in the human brain, namely musca- activity. Nicotinic receptors have been strongly associated rinic and nicotinic receptors, of which several subtypes with the modulation of depression and anxiety. occur. Conclusions Cholinergic receptor manipulations have an Objectives This review seeks to provide an overview of effect on cognition, emotion, and brain electrical activity as previous findings on the influence of cholinergic receptor measured by EEG. Changes in cognition can result from direct manipulations on cognition in animals and humans, with cholinergic receptor manipulation or from cholinergically particular emphasis on the role of selected cholinergic induced changes in vigilance or affective state. receptor subtypes. Furthermore, the involvement of these receptor subtypes in the regulation of emotion and brain Keywords nAChR . Nicotinic receptor . Acetylcholine electrical activity as measured by electroencephalography receptor . Vigilance . Cognition . Working memory . (EEG) shall be addressed since these domains are considered Attention . Depression . Anxiety to be important modulators of cognitive functioning. Results In regard to cognition, the muscarinic receptor Abbreviations subtypes have been implicated mainly in memory func- 5-CSRT Five-choice serial reaction time tions, but have also been linked to attentional processes.
    [Show full text]